London Stock Exchange Group PLC
Change company Symbol lookup
Select an option...
LDNXF London Stock Exchange Group PLC
JOE St. Joe Co
OMC Omnicom Group Inc
CHDN Churchill Downs Inc
SGTB Kuboo Inc
BBBMX BBH Limited Duration Fund Class N
VICI VICI Properties Inc
DDS Dillard's Inc
ALIN-E Altera Infrastructure LP
AUVGF Australian Vintage Ltd
Go

Financials : Capital Markets | Large Cap Growth
Based in United Kingdom
Company profile

London Stock Exchange Group PLC (LSEG) is a global financial markets infrastructure provider. LSEG operates across three divisions. Data & Analytics division provides customers with information and data products, and includes real-time and non-real-time data, pricing and reference services and indices, delivered via various distribution channels, including data feeds and desktop solutions. Data & Analytics consists of Trading & Banking Solutions, Investment Solutions, Wealth Solutions, Customer and 3rd Party Risk Solutions, and Enterprise Data Solutions. FTSE Russell is a global multi-asset class provider of indices, analytics and data solutions. Capital Markets division provides access to capital for domestic and international businesses and electronic platforms for secondary market trading of equities, fixed income and FX. Post Trade division provides clearing, settlement and regulatory reporting services to support clients’ risk and balance sheet management and regulatory reporting.

Closing Price
$100.53
Day's Change
1.18 (1.19%)
Bid
--
Ask
--
B/A Size
--
Day's High
101.07
Day's Low
99.97
Volume
(Light)
Volume:
2,808

10-day average volume:
16,533
2,808

Baxter Appoints Dr. David Wilkes to Its Board and Albert Stroucken as Lead Independent Director

4:30 pm ET February 16, 2021 (BusinessWire) Print

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced it has appointed David S. Wilkes, M.D., dean, University of Virginia School of Medicine, and co-founder and chief scientific officer of biotech start-up ImmuneWorks Inc., to its board of directors. Dr. Wilkes will serve on Baxter's Quality, Compliance and Technology Committee. Additionally, Baxter has appointed Albert P.L. Stroucken, former executive chairman and chief executive officer, Owens-Illinois, Inc., and a Baxter director since 2004, as its lead independent director. Mr. Stroucken, who previously served as the chairman of the Audit Committee, will succeed Thomas T. Stallkamp, who has served as lead independent director from May 2014 to February 2021. Mr. Stallkamp will continue to serve as a director of the board. Both new appointments are effective today and will bring the total number of directors serving the company to 13.

"We are pleased to welcome Dr. Wilkes to Baxter's board," said Jose (Joe) E. Almeida, chairman and chief executive officer. "His deep medical and research expertise, track record as a transformational leader, and distinguished career as an internationally recognized biotech entrepreneur will enhance and further diversify our current board membership. I'm confident his patient-centric approach and contributions will advance our Mission to save and sustain lives."

Added Mr. Almeida, "We extend our gratitude to Al for assuming the role as our new lead independent director. His experience as a former CEO and chair of Baxter's Audit Committee makes him uniquely suited to lead our board and provide management oversight. We also want to recognize Tom for his years of leadership and service as our lead independent director; his deep understanding of our business and the independence with which he has advanced this role have delivered tremendous value to Baxter and our stakeholders. We look forward to Tom's continued contributions to the board."

David S. Wilkes, M.D.

Dr. Wilkes currently serves as dean of the University of Virginia School of Medicine, where he has led the medical school's transformation, which has included targeted initiatives to improve funding and research endeavors as well as diversity programs. He is also co-founder and chief scientific officer of ImmuneWorks Inc., a biotech company developing novel therapeutics for immune-mediated lung diseases; and the national director of the Harold Amos Medical Faculty Program for the Robert Wood Johnson Foundation, one of the nation's leading programs in training physician scientists. Prior to these roles, Dr. Wilkes served in positions of increasing responsibility at Indiana University School of Medicine, where he focused on medical research. He received his bachelor's degree in biology from Villanova University, his medical degree from Temple University School of Medicine, and conducted his residency at Temple University Hospital. Dr. Wilkes completed a post-doctoral fellowship in pulmonary and critical care at University of Texas Southwestern Medical. He is also a military veteran, having served three years as a major in the U.S. Air Force Medical Corps. In 2020, Dr. Wilkes was elected to the prestigious National Academy of Medicine, one of the highest honors in the fields of health and medicine.

Albert P.L. Stroucken

Mr. Stroucken is former executive chairman of the board of directors of Owens-Illinois, Inc., where he also served as chairman, president and chief executive officer. Mr. Stroucken previously served as chairman, president and chief executive officer of H.B. Fuller Company, a manufacturer of adhesives, sealants, coatings, paints and other specialty chemicals. Prior to these positions, he held roles of increasing responsibility at Bayer AG and Bayer Corporation. Mr. Stroucken previously served as a director of Baxalta Incorporated and as a director of Shire plc until its acquisition by Takeda Pharmaceutical Company Limited in January 2019.

About Baxter

Every day, millions of patients and caregivers rely on Baxter's leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Baxter is a registered trademark of Baxter International Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210216006154/en/

SOURCE: Baxter International Inc.

Media Contact 
Stacey Eisen, (224) 948-5353
media@baxter.com

Investor Contact 
Clare Trachtman, (224) 948-3020
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.